Literature DB >> 23365113

Effect of Daikenchuto (TJ-100) on postoperative bowel motility and on prevention of paralytic ileus after pancreaticoduodenectomy: a multicenter, randomized, placebo-controlled phase II trial (the JAPAN-PD study).

Ken-ichi Okada1, Manabu Kawai, Katsuhiko Uesaka, Yasuhiro Kodera, Hiroaki Nagano, Yoshiaki Murakami, Satoshi Morita, Junichi Sakamoto, Hiroki Yamaue.   

Abstract

We conducted a multicenter, randomized, controlled trial in patients with pancreaticoduodenectomy to investigate the efficacy of Daikenchuto (TJ-100), which is a Kampo medicine (traditional Japanese herbal medicine), for its effect on postoperative bowel motility and for prevention of postoperative paralytic ileus. This clinical trial primarily evaluates the co-primary endpoints: (i) the incidence rate of postoperative paralytic ileus lasting over 72 h after surgery and (ii) time to having the first postoperative passage of flatus. The secondary endpoints are the incidence of postoperative paralytic ileus in cases that combined with/without enteral alimentation, QOL assessment by the Gastrointestinal Symptom Rating Scale (GSRS) Score (Japanese Version) and visual analogue scale, the change ratio of abdominal circumference, the incidence of postoperative complication, the number of postoperative hospital days, the incidence of surgical site infection and the incidence of postoperative small bowel obstruction within 2 years after surgery. Two hundred and twenty patients are required in the study (110 patients per group).

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23365113     DOI: 10.1093/jjco/hyt005

Source DB:  PubMed          Journal:  Jpn J Clin Oncol        ISSN: 0368-2811            Impact factor:   3.019


  6 in total

1.  Long-term Quality of Life and Gastrointestinal Functional Outcomes After Pancreaticoduodenectomy.

Authors:  Casey J Allen; Danny Yakoub; Francisco Igor Macedo; Austin R Dosch; Jessica Brosch; Vikas Dudeja; Ronda Ayala; Nipun B Merchant
Journal:  Ann Surg       Date:  2018-10       Impact factor: 12.969

2.  Intestinal, portal, and peripheral profiles of daikenchuto (TU-100)'s active ingredients after oral administration.

Authors:  Junko Watanabe; Noriko Kaifuchi; Hirotaka Kushida; Takashi Matsumoto; Miwako Fukutake; Mitsue Nishiyama; Masahiro Yamamoto; Toru Kono
Journal:  Pharmacol Res Perspect       Date:  2015-07-31

3.  Evaluation of QOL in Patients with Dyspeptic Symptoms Who Meet or Do Not Meet Rome IV Criteria.

Authors:  Masatoshi Mieno; Toshihiko Tomita; Sota Aono; Katsuyuki Tozawa; Keisuke Nakai; Takuya Okugawa; Masashi Fukushima; Tadayuki Oshima; Hirokazu Fukui; Hiroto Miwa
Journal:  J Clin Med       Date:  2021-12-22       Impact factor: 4.241

4.  Purinergic P2X7 receptor antagonist ameliorates intestinal inflammation in postoperative ileus.

Authors:  Hitomi Kimura; Takako Yamazaki; Taiki Mihara; Noriyuki Kaji; Kazuhisa Kishi; Masatoshi Hori
Journal:  J Vet Med Sci       Date:  2022-03-07       Impact factor: 1.267

Review 5.  Complementary and synergistic therapeutic effects of compounds found in Kampo medicine: analysis of daikenchuto.

Authors:  Toru Kono; Mitsuo Shimada; Masahiro Yamamoto; Atushi Kaneko; Yuji Oomiya; Kunitsugu Kubota; Yoshio Kase; Keiko Lee; Yasuhito Uezono
Journal:  Front Pharmacol       Date:  2015-08-04       Impact factor: 5.810

6.  Daikenchuto (TU-100) shapes gut microbiota architecture and increases the production of ginsenoside metabolite compound K.

Authors:  Takumu Hasebe; Nobuhiro Ueno; Mark W Musch; Anuradha Nadimpalli; Atsushi Kaneko; Noriko Kaifuchi; Junko Watanabe; Masahiro Yamamoto; Toru Kono; Yuhei Inaba; Mikihiro Fujiya; Yutaka Kohgo; Eugene B Chang
Journal:  Pharmacol Res Perspect       Date:  2016-02-10
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.